[China Pharmaceutical Network Technology News] On March 26, 2016, He Mei, an analyst at China International Capital Corporation, released an in-depth research report on US stocks. The report shows that although the biopharmaceutical sector in the stock market has been underperforming since last year due to the decline in market risk appetite and political factors, the fundamentals have not changed much, and the biotechnology innovation boom has remained. 
[Microsoft co-founder Paul Allen invests $100 million in biotechnology research]
Microsoft co-founder, current $15.3 billion investor and entrepreneur Paul Allen, announced that he will invest $100 million in the Paul G. Allen Frontiers Group to focus on future biotechnology research. Investment funds will allow the partners in the United States and the world to create a project, has created the Allen Discovery Centers and Allen Distinguished Investigators: the former will provide $ 30 million (of which 20 million will be gradually distributed in eight years) funding, with Stanford University and Tufts University cooperation; the latter is to provide 100 million to $ 1.5 million in funding to support early research, will work with UCSD, MIT, UCB and France's Institut du cerveau et de la Moelle épinière cooperation. Initial major research areas include the development of methods for reading and writing tissue and organ regeneration codes, the use of synthetic biology to combat deadly drug-resistant bacteria, the development of prototypes for bioinnovation, and the development of computational models to understand the multicellular basis of infectious diseases. (Techcrunch)
[Gene editor won the "Little Nobel Prize"]
Gairdner of Canada, with the reputation of "Little Nobel Prize", announced that three scientists, Zhang Feng, Jennifer Doudna and Emmanuelle Charpentier, have won the Gartner for their efforts to apply genetic editing CRISPRCas to eukaryotic cells. International awards. Three-year shared the Gairdner Foundation International Award and they have a French scientist Phillippe Horvath and North Carolina State University associate professor Rodolphe Barrangou, because they are "in the establishment of the system and a description CRISPRCas bacteria originally used for immune defense" and Award winning. Because there were patent disputes between Zhang Feng, Doudna, and Charpentier, the Gailner Foundation used the wording develop rather than “discoveryâ€. (Gairdner)
[Apple launched the medical application development framework CareKit]
Apple launched the medical application open source framework CareKit at the spring product launch last week. This open source tool will allow developers to further develop on four functions; help users record their physical therapy progress through sensors, and help patients simply record their clinical Symptoms, record the treatment effect and efficacy through CareCard, and share information between doctors and family members at any time. In contrast to Research Kit's focus on clinical research, CareKit focuses on chronic disease management, rehabilitation, etc., specifically for Parkinson's disease treatment, postoperative recovery, family health management, diabetes care, mental illness and maternal care. (Techcrunch)
[23andMe cooperates with Apple to enable users to analyze DNA data via iPhone]
23andMe, a genetic testing startup funded by Google, will allow users to share their genetic data with specific medical researchers using the iPhone. Currently cooperative medical research institutions including Stanford University School of Medicine, the Icahn SchoolofMedicineatMountSinai in New York and LifeMapSolutions and so on. When the user performs the specified operation on the iPhone, the user's genetic data will be passed from the 23andme database to the designated organization. Currently 23andme has more than one million users of genetic data. Previously these data were only stored in the company's own database. Gene data can be combined with other medical health data from users to play a greater role. At present, two research projects started sharing genetic data of the 23andme, namely "MyHeart Counts" and theIcahn School of Medicine at Stanford University School of Medicine's "AsthmaHealth", are using Apple's development of medical research ResearchKit App. The former has 50,000 volunteers, using mobile phones to record the time of walking, running and standing every week. After adding DNA data, the research team hopes to discover the effects of genetic factors on exercise. Apple's ResearchKit, launched in March 2015, currently has more than 20 applications. (TechnologyReview)
[Stemcentrx seeks strategies such as sale or IPO]
According to people familiar with the matter, Stemcentrx, a biotech startup focused on developing cancer stem cell-conjugated drugs, is seeking to sell itself or an IPO. The company is working with Morgan Stanley to discuss the sale and has received the first round of bids in early March. Late last year, the startup, backed by PayPal co-founder Peter Thiel, completed nearly $250 million in financing and was valued at $5 billion. Stemcentrx, if sold, will attract some large pharmaceutical companies to bid, and the company is expected to seek a higher price than the latest round of financing. In addition, the company may also choose to conduct an IPO. Founded in 2008, Stemcentrx currently has five cancer stem cell antibody-conjugated drugs in clinical trials. Three of the antibody drugs for small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer have been confirmed to have clinical efficacy. The species has also entered the first phase of clinical trials. Company investors include Peter Thiel, Artis Ventures and Founders Fund and so on. (The Wall StreetJournal)
ã€Electronic Skin Patch Controls Diabetes】
The researchers found a way to use electronic skin patches to detect excess glucose in sweat and to automatically manage drugs by heating microscopic needles that penetrate the skin, so that diabetics no longer need to pass their fingers frequently. Check blood sugar and inject drugs. The method was proposed by researchers at Seoul National University and MC10. Two years ago, the team also provided tremor diagnosis and storage of drugs in nanoparticles for patients with Parkinson's disease. The patch is made of graphene with gold particles and contains sensors for detecting humidity, glucose, pH, and temperature. The enzyme-based glucose sensor combines pH and temperature to improve detection accuracy. When the patch detects high glucose, the heater will activate and trigger the dissolution of the drug coat of the microneedle, causing the drug metformin to be released below the cortex. The only FDA-approved minimally invasive technique for detecting blood sugar was called Gluco Watch Biographer, which uses current to extract fluid from the underlying skin. It was approved in 2001, but was withdrawn from the market in 2007 due to complaints that the technique caused discomfort and pain. The University of North Carolina at Chapel Hill has also recently developed a nail-sized patch that carries more than 100 microneedles consisting of microcapsules containing insulin and an enzyme. When glucose in the blood penetrates into the sac, the enzyme converts glucose into an acid that dissolves the sac, releasing insulin. In contrast to this approach, MC10 can also store and transfer data from drug injections to wearables and smartphones. (Technology Review)
[The first test of optogenetic therapy in humans]
A blind woman in Texas became the first patient to receive optogenetic therapy at the end of February. If successful, the therapy will create photoreceptor cells in their eyes to reproduce. This patient and other patients undergoing clinical trials have a degenerative disease of retinitis pigmentosa, a condition in which a photoreceptor cell that conducts electrical signals to nerve cells gradually dies. Therapy uses optogenetic techniques to accurately control nerves based on gene therapy and light, which can make a particular cell sensitization of a ganglion cell in a female patient's eye. The patient's eyes are filled with a virus carrying photosynthetic algae DNA. After successful, the cell will replace the function of rods and cones on healthy retina, react to light and emit electrical signals and image in the brain, but the therapy only It enables the patient to gain partial visual perception rather than full color vision. In the coming year, the Retina Foundation's doctors will continue to monitor the patient's eye sensitivity and may need to inject an additional three doses for treatment. They will also observe if there are any side effects. Currently, the condition can only be treated by implanting a retinal prosthesis to stimulate the eye cells. In addition to blind treatment, the trial has also been the focus of neuroscience, and optogenetics may be used in diseases such as Parkinson's and schizophrenia.
[Microsoft co-founder Paul Allen invests $100 million in biotechnology research]
Microsoft co-founder, current $15.3 billion investor and entrepreneur Paul Allen, announced that he will invest $100 million in the Paul G. Allen Frontiers Group to focus on future biotechnology research. Investment funds will allow the partners in the United States and the world to create a project, has created the Allen Discovery Centers and Allen Distinguished Investigators: the former will provide $ 30 million (of which 20 million will be gradually distributed in eight years) funding, with Stanford University and Tufts University cooperation; the latter is to provide 100 million to $ 1.5 million in funding to support early research, will work with UCSD, MIT, UCB and France's Institut du cerveau et de la Moelle épinière cooperation. Initial major research areas include the development of methods for reading and writing tissue and organ regeneration codes, the use of synthetic biology to combat deadly drug-resistant bacteria, the development of prototypes for bioinnovation, and the development of computational models to understand the multicellular basis of infectious diseases. (Techcrunch)
[Gene editor won the "Little Nobel Prize"]
Gairdner of Canada, with the reputation of "Little Nobel Prize", announced that three scientists, Zhang Feng, Jennifer Doudna and Emmanuelle Charpentier, have won the Gartner for their efforts to apply genetic editing CRISPRCas to eukaryotic cells. International awards. Three-year shared the Gairdner Foundation International Award and they have a French scientist Phillippe Horvath and North Carolina State University associate professor Rodolphe Barrangou, because they are "in the establishment of the system and a description CRISPRCas bacteria originally used for immune defense" and Award winning. Because there were patent disputes between Zhang Feng, Doudna, and Charpentier, the Gailner Foundation used the wording develop rather than “discoveryâ€. (Gairdner)
[Apple launched the medical application development framework CareKit]
Apple launched the medical application open source framework CareKit at the spring product launch last week. This open source tool will allow developers to further develop on four functions; help users record their physical therapy progress through sensors, and help patients simply record their clinical Symptoms, record the treatment effect and efficacy through CareCard, and share information between doctors and family members at any time. In contrast to Research Kit's focus on clinical research, CareKit focuses on chronic disease management, rehabilitation, etc., specifically for Parkinson's disease treatment, postoperative recovery, family health management, diabetes care, mental illness and maternal care. (Techcrunch)
[23andMe cooperates with Apple to enable users to analyze DNA data via iPhone]
23andMe, a genetic testing startup funded by Google, will allow users to share their genetic data with specific medical researchers using the iPhone. Currently cooperative medical research institutions including Stanford University School of Medicine, the Icahn SchoolofMedicineatMountSinai in New York and LifeMapSolutions and so on. When the user performs the specified operation on the iPhone, the user's genetic data will be passed from the 23andme database to the designated organization. Currently 23andme has more than one million users of genetic data. Previously these data were only stored in the company's own database. Gene data can be combined with other medical health data from users to play a greater role. At present, two research projects started sharing genetic data of the 23andme, namely "MyHeart Counts" and theIcahn School of Medicine at Stanford University School of Medicine's "AsthmaHealth", are using Apple's development of medical research ResearchKit App. The former has 50,000 volunteers, using mobile phones to record the time of walking, running and standing every week. After adding DNA data, the research team hopes to discover the effects of genetic factors on exercise. Apple's ResearchKit, launched in March 2015, currently has more than 20 applications. (TechnologyReview)
[Stemcentrx seeks strategies such as sale or IPO]
According to people familiar with the matter, Stemcentrx, a biotech startup focused on developing cancer stem cell-conjugated drugs, is seeking to sell itself or an IPO. The company is working with Morgan Stanley to discuss the sale and has received the first round of bids in early March. Late last year, the startup, backed by PayPal co-founder Peter Thiel, completed nearly $250 million in financing and was valued at $5 billion. Stemcentrx, if sold, will attract some large pharmaceutical companies to bid, and the company is expected to seek a higher price than the latest round of financing. In addition, the company may also choose to conduct an IPO. Founded in 2008, Stemcentrx currently has five cancer stem cell antibody-conjugated drugs in clinical trials. Three of the antibody drugs for small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer have been confirmed to have clinical efficacy. The species has also entered the first phase of clinical trials. Company investors include Peter Thiel, Artis Ventures and Founders Fund and so on. (The Wall StreetJournal)
ã€Electronic Skin Patch Controls Diabetes】
The researchers found a way to use electronic skin patches to detect excess glucose in sweat and to automatically manage drugs by heating microscopic needles that penetrate the skin, so that diabetics no longer need to pass their fingers frequently. Check blood sugar and inject drugs. The method was proposed by researchers at Seoul National University and MC10. Two years ago, the team also provided tremor diagnosis and storage of drugs in nanoparticles for patients with Parkinson's disease. The patch is made of graphene with gold particles and contains sensors for detecting humidity, glucose, pH, and temperature. The enzyme-based glucose sensor combines pH and temperature to improve detection accuracy. When the patch detects high glucose, the heater will activate and trigger the dissolution of the drug coat of the microneedle, causing the drug metformin to be released below the cortex. The only FDA-approved minimally invasive technique for detecting blood sugar was called Gluco Watch Biographer, which uses current to extract fluid from the underlying skin. It was approved in 2001, but was withdrawn from the market in 2007 due to complaints that the technique caused discomfort and pain. The University of North Carolina at Chapel Hill has also recently developed a nail-sized patch that carries more than 100 microneedles consisting of microcapsules containing insulin and an enzyme. When glucose in the blood penetrates into the sac, the enzyme converts glucose into an acid that dissolves the sac, releasing insulin. In contrast to this approach, MC10 can also store and transfer data from drug injections to wearables and smartphones. (Technology Review)
[The first test of optogenetic therapy in humans]
A blind woman in Texas became the first patient to receive optogenetic therapy at the end of February. If successful, the therapy will create photoreceptor cells in their eyes to reproduce. This patient and other patients undergoing clinical trials have a degenerative disease of retinitis pigmentosa, a condition in which a photoreceptor cell that conducts electrical signals to nerve cells gradually dies. Therapy uses optogenetic techniques to accurately control nerves based on gene therapy and light, which can make a particular cell sensitization of a ganglion cell in a female patient's eye. The patient's eyes are filled with a virus carrying photosynthetic algae DNA. After successful, the cell will replace the function of rods and cones on healthy retina, react to light and emit electrical signals and image in the brain, but the therapy only It enables the patient to gain partial visual perception rather than full color vision. In the coming year, the Retina Foundation's doctors will continue to monitor the patient's eye sensitivity and may need to inject an additional three doses for treatment. They will also observe if there are any side effects. Currently, the condition can only be treated by implanting a retinal prosthesis to stimulate the eye cells. In addition to blind treatment, the trial has also been the focus of neuroscience, and optogenetics may be used in diseases such as Parkinson's and schizophrenia.
alpha arbutin .kojic acid powder .nmn powder.coenzyme q10 powder. glutathione powder .apigenin powder. aloe vera gel freeze dried powder etc
Cosmetic Ingredients,Strawberry Powder,Kojic Acid Powder,Glutathione Powder
Youth Biotech CO,. Ltd. , https://www.youtherb.com